Press Release
Luxuri Awards Names AirportAssist the Best VVIP Airport Meet and Greet Service in Europe 2025
London, United Kingdom, 25th Apr 2025 – Luxuri Awards proudly announces AirportAssist.com as the recipient of the Best VVIP Airport Meet & Greet Service Award – Europe 2025. This prestigious accolade honours the brand’s remarkable contribution to redefining luxury travel, offering travellers an experience marked by comfort, precision, and exclusivity.
Founded in 2014, AirportAssist.com has rapidly established itself as a global leader in the premium airport services sector. With operations spanning 1,156 airports across 195 countries, the company delivers a robust range of concierge-style solutions, including VVIP, VIP, and CIP assistance, as well as Meet and Greet, Fast Track services, security and immigration clearance, lounge access, baggage handling, airport transfers, and personalised transit support.
Serving an elite clientele that includes royalty, billionaires, political figures, celebrities, and top-tier executives, AirportAssist.com is equally committed to catering to everyday travellers seeking tailored service. Its dedication to operational excellence and customer-centric innovation has consistently positioned it as the preferred provider for seamless airport experiences worldwide.
The Luxuri Awards are a symbol of distinction in the world of modern luxury. Created to celebrate the brands and individuals driving innovation and excellence across industries, the awards spotlight leaders in travel, hospitality, fashion, wellness, and beauty, among others. Nominees are carefully selected through a multi-layered process led by Luxuri’s editorial and research teams, who rely on insights from trusted media partners, industry thought leaders, and publicly available data.
In selecting the winner of the Best VVIP Airport Meet & Greet Service – Europe 2025, Luxuri focused on three key pillars: innovation, customer experience, and impact on luxury travel. AirportAssist.com emerged as the clear front-runner, thanks to its seamless integration of premium services, global reach, and consistently positive client feedback.
Reflecting on the honour, Sunitha Markose, CEO and Co-founder of AirportAssist.com, shared:
“Winning the Best VVIP Airport Meet & Greet Service Award – Europe 2025 is a proud moment for all of us at AirportAssist.com. This award reflects our team’s unwavering dedication to crafting seamless and memorable airport experiences for every traveller. It motivates us to continue setting new benchmarks in exceptional care and service at each of the 1,156 airports we serve.”
About AirportAssist.com
AirportAssist.com is a global provider of premium airport concierge services, established in 2014. With operations across 1,156 airports in 195 countries, the brand specializes in VVIP, VIP, and CIP assistance tailored for arrivals, departures, and transits. Services include Meet and Greet, Fast Track, Immigration Clearance, Baggage Assistance, Airport Transfers, and Lounge Access. Designed for discerning travellers, from heads of state to everyday flyers, AirportAssist.com redefines how the world experiences airports. Learn more at www.airportassist.com.
About Luxuri Awards
The Luxuri Awards recognise trailblazing brands and individuals who are transforming the global luxury landscape. With a rigorous selection process that combines editorial curation and data-driven research, Luxuri spotlights excellence across travel, lifestyle, fashion, beauty, wellness, and design. Each award symbolises innovation, influence, and enduring impact in the luxury sector. Explore more at www.luxuriawards.com.
Media Contact
Organization: Luxuri
Contact Person: James Winslow
Website: https://www.luxurimag.com
Email: Send Email
City: London
Country:United Kingdom
Release id:26902
View source version on King Newswire:
Luxuri Awards Names AirportAssist the Best VVIP Airport Meet and Greet Service in Europe 2025
It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
BioLight Launches BioLithin A Breakthrough Mitochondrial Supplement for Energy Muscle Health and Longevity
United States, 17th Sep 2025 – BioLight, an innovative leader in advanced health and longevity solutions, proudly announces the launch of BioLithin, a next-generation mitochondrial supplement designed to strengthen cellular resilience, boost energy, and support long-term vitality.
BioLithin is formulated with a unique combination of Urolithin A, Urolithin B, and Taurine, all carefully selected and dosed based on the latest scientific research. By targeting mitochondrial renewal and optimizing cellular function, BioLithin provides a powerful defense against the natural decline in energy, muscle health, and cognitive function that comes with aging.
A Revolutionary Approach to Mitochondrial Health
Mitochondria, often referred to as the “powerhouses” of the cell, play a vital role in energy production, metabolism, and longevity. As people age, mitochondrial efficiency declines, leading to fatigue, reduced strength, and increased vulnerability to age-related conditions. BioLithin was created to address this challenge directly, helping individuals renew their mitochondrial health from the inside out.
The supplement works through three core mechanisms:
- Mitochondrial Renewal – Promotes recycling and creation of new mitochondria, enhancing energy efficiency and endurance.
- Longevity Defense – Combats inflammation and oxidative damage, two of the biggest contributors to cellular aging.
- Neuroprotection – Activates brain-supportive pathways that help defend against cognitive decline and promote mental clarity.
A Synergistic Blend of Science-Backed Ingredients
What sets BioLithin apart is its groundbreaking combination of Urolithin A, Urolithin B, and Taurine:
- Urolithin A – Shown in clinical studies to support mitochondrial biogenesis and improve muscle endurance, making it a cornerstone in longevity science.
- Urolithin B – A rare, naturally occurring compound that complements Urolithin A, supporting muscle growth and protein synthesis.
- Taurine – A powerful amino acid linked to cellular hydration, heart health, and brain function, recently highlighted in longevity research as essential for healthy aging.
Unlike other supplements that use general extracts, BioLight sources ultra-high purity Urolithins from pomegranate peel—the most efficacious portion of the fruit for delivering these compounds. This ensures that every capsule of BioLithin offers unmatched potency and consistency.
Rooted in Cutting-Edge Research
Every ingredient and dosage in BioLithin is backed by the latest peer-reviewed science. Studies have demonstrated the profound effects of Urolithins on mitochondrial renewal, muscle health, and cognitive vitality. By combining these compounds with Taurine, BioLight has created a supplement that not only supports longevity but also empowers individuals to stay active, resilient, and mentally sharp as they age.
“With BioLithin, we’re taking mitochondrial health to the next level,” said Don Bailey, spokesperson for BioLight. “This product was designed for those who want to maintain peak energy, strength, and cognitive performance throughout their lives. We believe BioLithin represents a new frontier in longevity science, giving people the tools to age better, stronger, and smarter.”
Availability
BioLithin is now available exclusively through the BioLight official website. Customers can explore detailed product information, scientific references, and purchase options directly from the site.
About BioLight
Founded with a mission to advance human longevity through science-based nutrition, BioLight develops innovative supplements that target the root causes of cellular aging. By combining cutting-edge research with high-purity ingredients, BioLight is redefining what’s possible in proactive health and wellness. The company is committed to helping people achieve optimal vitality and resilience at every stage of life.
Media Contact
Organization: BioLight
Contact Person: Don Bailey
Website: https://www.biolight.shop/
Email: Send Email
Country:United States
Release id:34071
Disclaimer: This press release is for informational purposes only and does not constitute medical advice. The product described is a dietary supplement, not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a qualified healthcare professional before starting any new supplement regimen.
The post BioLight Launches BioLithin A Breakthrough Mitochondrial Supplement for Energy Muscle Health and Longevity appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Savitri Network Officially Launches and Opens Private Sale on September 15, 2025
Astana, Kazakhstan, 17th September 2025, ZEX PR WIRE, Savitri Network, a next-generation blockchain with a dual-token model, officially launched on September 15, 2025, at 12:00 PM UTC+0. The highly anticipated event introduces a unique and innovative approach to blockchain technology and also kicks off the private sale of the blockchain’s native token, $SAVI, giving crypto enthusiasts the opportunity to join the project in its early stages.
Savitri Network seamlessly combines artificial intelligence (AI), Internet of Things (IoT) capabilities, and governance convergence into a single, sustainable ecosystem, driving real-world adoption of blockchain technology. The project aims to go beyond the common use of blockchain networks, which are often focused primarily on financial transactions.
Savitri Network supports predictable, ultra-low transaction costs, seamless IoT data integration, and AI-powered services directly on-chain. These features expand its use cases beyond financial operations. As a result, the network has the potential to serve as the foundational operating layer for various real-world industries, including logistics, healthcare, and supply chain management.
Key features of Savitri Network include:
- Dynamic staking rewards that adjust over time (8% → 5% → 3%) to balance incentives and sustainability.
- Enterprise-ready design: A fixed transaction fee of $0.0035 per transaction, making blockchain integration viable at scale.
- High-speed performance: 230,000 transactions per second (TPS) with confirmation in just 836 milliseconds.
- Energy efficiency: Up to 95% lower energy consumption compared to most blockchains.
- Developer-friendly tools: Easy-to-use APIs and SDKs for seamless developer access.
- Broad technological support: Real-world interoperability between IoT devices, AI models, and enterprise systems.
One of Savitri Network’s most notable innovations is its dual-token model, centered around two robust tokens: $SAVI and $VOTE.
- The $SAVI coin is the backbone of the Savitri Network ecosystem. It is designed to power transactions, staking, AI model payments, and IoT services. With a total supply of 2 billion $SAVI coins and a 50-year emission model with adaptive deflation, $SAVI ensures both stability and longevity. Ten percent of the total supply is allocated to the private sale, which begins on launch day.
- The $VOTE token is built to enable transparent, community-driven governance. It allows holders to influence the network’s future and earn rewards by participating in governance processes. $VOTE uses a quadratic voting system and incorporates a deflationary burn mechanism that reduces supply over time.
Savitri Network employs Proof-of-Unity (PoU) as its consensus mechanism, designed for speed, fairness, and inclusivity. PoU ensures fast, low-cost, and eco-friendly validation without the need for mining, complex staking, or centralized authority. Instead, it encourages collaboration, minimizes energy waste, and promotes true decentralization.
The team behind Savitri Network emphasizes that it is building an innovative blockchain designed to last for the next 100 years, with a focus on real-world adoption and purpose-driven innovation.
Join the $SAVI Coin private sale and become part of the project at the very start of its promising journey. The event features structured vesting, ensuring investor protection and fostering long-term value creation for the token.
About Savitri Network
Savitri Network’s blockchain stands out with its infrastructure optimized for real-world enterprise adoption. The project appeals to crypto enthusiasts seeking ethical and scalable initiatives, as well as developers building on-chain, AI-driven, or IoT-based applications. In the future, Savitri Network aims to support enterprises and governments seeking traceability and ESG compliance.
The Savitri Network team encourages communities in emerging markets and forward-looking investors to join its purpose-driven infrastructure built for utility and longevity.
Learn more about Savitri Network on its official website and social media channels: X, Telegram, Discord, LinkedIn, Medium, and YouTube.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Open Doors to the Asian Market: Seoul Bio Hub-Celltrion Launches ‘Global Open Innovation’ for U.S. Startups
Seoul Bio Hub and Celltrion Launch Strategic Gateway ‘Global Open Innovation’ to Help U.S. Bio Startups Dominate the Asian Market
Two U.S.-Based Biotech and Medical Device Startups to Be Selected Based on Technology Alignment with Celltrion’s Expertise in Antibodies, Peptides, and Drug Formulation
Seoul, Korea – 17/09/2025 – (SeaPRwire) – Seoul’s bio startup hub ‘Seoul Bio Hub’ and global pharmaceutical leader ‘Celltrion’ have joined forces to launch the ‘2025 Seoul Bio Hub-Celltrion Global Open Innovation (GOI)’ program. This program goes beyond a simple competition, serving as a platform designed to help U.S. startups successfully establish themselves in the Asian market.
This GOI targets U.S.-based bio and medical startups, with companies established within the past 7 years eligible to apply. The recruitment areas encompass all technologies suitable for collaboration with Celltrion, including antibodies, peptides, small molecules, formulations, and cell and gene therapies.
The application deadline is September 30, 2025. The selection process will proceed in the following order:
- Primary document evaluation
- Technology review
- Secondary presentation evaluation.
The two finally selected companies will receive customized follow-up support and gain opportunities to expand into global markets through collaboration with Celltrion, leveraging South Korea’s innovative ecosystem and global capabilities.
A Seoul Bio Hub representative stated, “This program will serve as a bridgehead that goes beyond simple space support, enabling U.S. startups to rapidly grow in the Asian market by leveraging Seoul’s excellent clinical infrastructure and research environment.”
A Celltrion representative announced, “Based on Celltrion’s capabilities and know-how accumulated across the entire pharmaceutical industry process including R&D, production, and sales, we will support promising U.S. startups to successfully enter the Asian market and create synergy with our company.”
South Korea has established itself as a bio hub leading the global market with clear numerical evidence. According to global consulting firm Intralink, South Korea’s biopharmaceutical market is valued at approximately $22 billion, ranking 13th globally.
Additionally, market research firm Grand View Research forecasts that South Korea’s biotechnology market will grow to $81.6 billion (approximately 110 trillion KRW) by 2030, representing an annual average growth rate of 18.3%.
Private investment is also active. From 2020 to 2022, R&D and facility investments recorded an annual average growth rate of 21.6%. This demonstrates that South Korea is not merely a potential market, but a rapidly growing innovation ecosystem.
According to ClinicalTrials.gov, the global clinical trial database, Seoul has consistently maintained a top position among major global cities in the number of new clinical trials over the past decade.
South Korea’s Ministry of Health and Welfare has set ‘Achieving Global 3rd Place in Clinical Trials’ as a policy objective through the ‘3rd Five-Year Plan for the Pharmaceutical and Bio Industry (2023-2027)’. Furthermore, in 2025, it raised a total of over 386.6 billion KRW through the ‘Bio Health Mega Fund’ and is actively supporting innovative companies’ clinical trials and commercialization through the national integrated bio big data construction project and AI, bio health regulatory regulatory sandboxes.
Seoul Bio Hub is a bio startup support organization established by Seoul City in 2017. It provides 251 pieces of shared laboratory equipment and affordable tenant space at 10% of the cost compared to major areas in Seoul. As of May 2025, it has supported 322 startups and attracted a total of 576 billion KRW in follow-up investment, proving its potential for success.
Celltrion is South Korea’s global comprehensive biotechnology company that developed the world’s first antibody biosimilar ‘Remsima’. The company performs the entire process from research and development to approval, production, and sales, supplying high-quality biopharmaceuticals to over 100 countries worldwide. Based on world-class research and production infrastructure, it contributes to expanding global access to pharmaceuticals and continues to support and collaborate with promising startups through active open innovation strategies.
For detailed information regarding program applications and inquiries, please access LinkedIn, search for ‘Seoul Bio Hub’, and check the 「2025 Seoul Bio Hub-Celltrion Global Open Innovation」 recruitment announcement posted on the official company page.
About Seoul Bio Hub
https://www.seoulbiohub.kr/front/user/engmain.do
Establishment Date: October 30, 2017
Operating Entity: Established by Seoul City / Joint operation by KIST and Korea University
Location: 117-3 Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea
Purpose: Growth and commercialization support for early-stage bio and healthcare startups under 10 years
Tenant Companies (As of June 2025): Total 126 companies (Digital Health 42 companies (33.3%), Pharmaceuticals 61 companies (48.5%), Medical Devices 23 companies (18.2%))
Infrastructure: Laboratories, office spaces, meeting rooms, conference rooms, research equipment (249 devices, 109 types, approximately $8 million scale)
Research and Human Resource Network (Regional): Approximately 7,000 PhD-level personnel, approximately 120,000 university students, $1.13 billion in research funding, connections with 12 universities and research institutions and 7 hospitals
Major Support Programs:
- IR matching and investment linkage
- Expert consulting and CEO education
- Hospital-linked clinical and data programs
- Open innovation with domestic and international pharmaceutical companies
About Celltrion
https://www.celltrion.com/en-us
Establishment Date: February 26, 2002
Location (Headquarters): 23 Academy-ro, Yeonsu-gu, Incheon Metropolitan City, Republic of Korea
Business Areas and Major Products (Services)
Possessing Differentiated Integrated Solutions Across the Entire Biopharmaceutical Business Process
- Remsima: World’s first monoclonal antibody biosimilar (TNF-α inhibitor)
- Herzuma: Trastuzumab biosimilar for breast and gastric cancer treatment
- Truxima (CT-P10): Rituximab biosimilar (lymphoma, rheumatoid arthritis, etc.)
- Multiple products including Zymfentra, Yuflyma, Vegzelma, Steqeyma, Avtozma are under global approval and commercialization
No of Employees: Approx. 3,003 (As of June 30, 2025)
Media Contact
Brand: SEOUL BIO HUB
Contact: Lee Yoon Jin
Phone: +82 02-2200-3345
Email: lynj@kist.re.kr
Website: (KOR) https://www.seoulbiohub.kr/front/user/main.do;
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Talisman Brings Built-In Crypto AI Agents to the Wallet
-
Press Release7 days ago
Earn $7,700 a day: BJMINING revolutionizes Bitcoin passive income with cloud mining
-
Press Release2 days ago
Software Applications Launches All-in-One Business Management Platform to Simplify Operations for Businesses of All Sizes
-
Press Release1 week ago
Talisman Brings Built-In Crypto AI Agents to the Wallet
-
Press Release7 days ago
Swanson Reed Acquires AusGrant Strengthening Its Position as a Global Leader in R&D and Innovation Funding
-
Press Release7 days ago
How WinnerMining Makes Passive Income from BTC and XRP Simple and Transparent
-
Press Release4 days ago
More Than Metrics: Elliot Ambalo’s Blueprint for Long-Term Brand Loyalty
-
Press Release3 days ago
Rocketta Confirms September 19 Launch Date for Frontier Alpha ETF (in Strategic Deal with Altimor Asset Strategies), Investor Demand Surges Ahead of Trading Window